同仁堂系全線暴漲 同仁堂集團擬開拓醫藥電商業務
格隆匯5月26日丨港A同仁堂系股票全線暴漲,同仁堂科技大漲11.21%,同仁堂科技旗下同仁堂國藥漲12%;同仁堂國藥母公司,A股上市的同仁堂(600085.SH)更是早早便漲停,現報41.47元。同仁堂科技與同仁堂股份、同仁堂商業及白兔信息,分別出資1250萬、1250萬、1300萬和1200萬元,成立合資公司,從事醫藥電商業務,而上述公司分別持有合營的25%、25%、26%及24%持股。同仁堂股份直接持有同仁堂科技46.85%股權,同仁堂股份則持有同仁堂商業51.98%股權。公吿稱,成立合資公司可整合同仁堂集團系統內部和外部資源,有助於實現資源的優化配置,逐步形成同仁堂醫藥電子商務產業一體化平台,擴大品牌影響力、拉動產品線上銷售,滿足該公司未來業務需求,並有助於進一步提升該公司業務的長期發展。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.